X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Columvi (glofitamab) is a CD20xCD3 T-cell engaging bispecific antibody, which is being evaluated in combination with chemotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Lead Product(s): Glofitamab,Obinutuzumab,Tocilizumab
Therapeutic Area: Oncology Product Name: Columvi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. It is being evaluated in combination with venetoclax for the treatment of higher-risk myelodysplastic syndromes & chronic myelomonocytic leukemia.
Lead Product(s): Decitabine,Cedazuridine,Venetoclax
Therapeutic Area: Oncology Product Name: Inqovi
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Astex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Lunsumio (mosunetuzumab) is a CD20xCD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. It is being evaluated for the treatment of relapsed and refractory follicular lymphoma.
Lead Product(s): Mosunetuzumab
Therapeutic Area: Oncology Product Name: Lunsumio
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
Vabysmo® (faricimab-svoa) is a bispecific antibody that inhibits Ang-2 & VEGF-A pathways. It is being evluated in phase 3 clinical trials for the treatment of macular edema due to branch and central retinal vein occlusion.
Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: Vabysmo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
The companies will employ GenEdit’s NanoGalaxy platform to discover and develop novel nanoparticles to deliver Genentech’s nucleic acid-based medicines for treatment of autoimmune disease.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: GenEdit
Deal Size: $644.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration January 23, 2024
Details:
Through the termination, AC Immune will regain all global rights to the anti-amyloid beta antibody RO5490245 (crenezumab) and the anti-Tau antibody semorinemab. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD).
Lead Product(s): Crenezumab
Therapeutic Area: Neurology Product Name: RO5490245
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: AC Immune
Deal Size: $418.0 million Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2024
Details:
Hemlibra (Emicizumab-kxwh) is a bispecific monoclonal antibody designed to bind factor IXa and factor X. In doing so, Hemlibra provides the cofactor function of factor VIII in people with hemophilia A, who either lack or have impaired coagulation function of factor VIII.
Lead Product(s): Emicizumab
Therapeutic Area: Genetic Disease Product Name: Hemlibra
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2023
Details:
GDC-0077 (inavolisib) is an investigational, highly selective inhibitor and degrader of mutant PI3K alpha. It is being evaluated in combination with palbociclib & fulvestrant for the treatment of HER2-negative breast cancer With a PIK3CA Mutation.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: GDC-0077
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate. It is being evaluated for the treatment of HER2-positive early-stage breast cancer With residual invasive disease after neoadjuvant treatment.
Lead Product(s): Kadcyla
Therapeutic Area: Oncology Product Name: Kadcyla
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
GDC-0077 (inavolisib palbociclib fulvestrant) is a PI3K alpha Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer with a PIK3CA mutation via oral tablet.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: GDC-0077
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
